Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
World Congress on Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS-LACTRIMS)
Early, Long-term Treatment Advised for Multiple Sclerosis
Montreal, Quebec / September 17-20, 2008
Montreal - Immune-modulating therapies for multiple sclerosis (MS) improve relapse rate, progression to disability and burden of disease on magnetic resonance imaging. Evidence presented at this meeting supports the practice of employing...
11th International Conference on Alzheimer’s Disease (ICAD)
Prevention and Mitigation of Alzheimer’s Disease Behavioural Symptoms
Chicago, Illinois / July 26-31, 2008
Chicago - Behavioural or psychiatric disturbances are common in patients with Alzheimer’s disease (AD). Distressing for both patient and caregiver, they often necessitate increased healthcare resources and costs as well as institutional...
50th Annual Scientific Meeting of the American Headache Society
New Targets and Strategies for the Prevention and Treatment of Migraine
Boston, Massachusetts / June 26-29, 2008
Boston - Once thought of as a primarily vascular disorder, migraine is now recognized as a complex, multifactorial condition with both neurologic and vascular substrates. Current understanding of the neural processes and pain-perception...
PRIORITY PRESS - 22nd Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC)
Patients with Multiple Sclerosis Benefit from Early Treatment and Support to Improve Adherence
Denver, Colorado / May 28-31, 2008
Multiple sclerosis (MS) is a chronic progressive disease process with subclinical degeneration and axonal loss. The current paradigm for treating MS is to intervene early at the first clinical episode, i.e. clinically isolated syndrome...
28th Annual Conference of the Canadian Pain Society
Management of Central Neuropathic Pain, Fibromyalgia and Chronic Allodynia: Examining Modulation of the Endocannabinoid System
Victoria, British Columbia / May 27-30, 2008
Victoria - The discovery of the physiological functions of the endocannabinoid system in the central and peripheral nervous systems and peripheral organs has created opportunities to develop and study new treatment alternatives in a variety...
60th Annual Meeting of the American Academy of Neurology
Multiple Sclerosis Treatment Beneficial for Patients with Early Signs of Disease
Chicago, Illinois / April 12-19, 2008
Chicago - A strategy of watchful waiting for patients with suspected multiple sclerosis (MS) is being challenged, with convincing data to support the use of early treatment in order to postpone disability progression in the clinically...
60th Annual Meeting of the American Academy of Neurology
Update on Treatment of Clinically Isolated Syndrome and Relapsing-remitting Multiple Sclerosis
Chicago, Illinois / April 12-19, 2008
Chicago - A new study conducted in patients with clinically isolated syndrome revealed that glatiramer acetate (GA) was effective in preventing conversion to clinically definite multiple sclerosis (MS). The greater efficacy of GA compared...
MEDICAL OPTIONS Cardiovascular Risk Factors
The Kidney-Heart-Brain Axis: Update on RAS Inhibition
February 2008
The Essence of RAS Inhibition in Hypertension Dr. Lyall Higginson, Royal Jubilee Hospital The Renin-angiotensin System in Diabetes Dr. Sheldon Tobe, University of Toronto Maximizing Nephroprotection: The Role of RAS Inhibition Dr. Paul René...
17th World Congress on Parkinson’s Disease and Related Disorders
Optimizing Treatment Outcomes at Different Stages of Parkinson’s Disease
Amsterdam, The Netherlands / December 9-13, 2007
Amsterdam - Parkinson’s disease is a common neurodegenerative disease, thought to affect about 1% of those aged ³65 years. The disease is caused by depleted dopamine concentrations in the brain, which leads to impaired neurotransmission and...